Heparin

Generic Name: Heparin

Brand Names: Heparin Leo

Drug Type: Small Molecule

Chemical Formula: -

CAS Number: 9005-49-6

Unique Ingredient Identifier: T2410KM04A

Background: Unfractionated heparin (UH) is a heterogenous preparation of anionic, sulfated glycosaminoglycan polymers with weights ranging from 3000 to 30,000 Da. It is a naturally occurring anticoagulant released from mast cells. It binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin (fac...

Indication: Unfractionated heparin is indicated for prophylaxis and treatment of venous thrombosis and its extension, prevention of post-operative deep venous thrombosis and pulmonary embolism and prevention of clotting in arterial and cardiac surgery. In cardiology, it is used to prevent embolisms in patients with atrial fibrillation and as an adjunct antithrombin ther...

Associated Conditions: Blunt Injury, Clotting, Coagulopathy, Consumption, Contusions, Deep vein thrombosis postoperative, Disseminated Intravascular Coagulation (DIC), External Hemorrhoid, Inflammation, Inflammatory, non-infectious pruritic dermatosis, Interstitial Cystitis, Post procedural pulmonary embolism, Pulmonary Embolism, ST Segment Elevation Myocardial Infarction (STEMI), Sprains, Thromboembolism, Unstable Angina Pectoris, Venous Thrombosis (Disorder), Hematomas, Peripheral arterial embolism, Thromboembolic phenomena, Varicosities of the great saphenous vein

Associated Therapies: Circulation, Extracorporeal, Dialysis therapy, Transfusions, Maintenance of patency of IV injection devices

Clinical Trials

Effect of Elevated Plasma-Free-Fatty-Acids on Renal Hemodynamic Parameters

Not Applicable

Completed

Conditions: Renal Circulation
Renal Plasma Flow
Glomerular Filtration Rate
Fatty Acids, Nonesterified

First Posted Date: 2007-02-06

Last Posted Date: 2007-02-06

Lead Sponsor: Medical University of Vienna

Target Recruit Count: 9

Registration Number: NCT00431665

Locations: 🇦🇹
Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria

Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related Infection

Not Applicable

Withdrawn

Conditions: Cancer

Interventions: Drug: Minocycline-EDTA
Drug: Heparin

First Posted Date: 2006-09-21

Last Posted Date: 2012-02-24

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT00378781

Randomized Comparison of Abciximab Plus Heparin With Bivalirudin in Acute Coronary Syndrome

Phase 4

Completed

Conditions: Coronary Disease
Myocardial Infarction

Interventions: Drug: Abciximab + UFH
Drug: Bivalirudin
Drug: Heparin

First Posted Date: 2006-09-08

Last Posted Date: 2012-05-08

Lead Sponsor: Deutsches Herzzentrum Muenchen

Target Recruit Count: 1721

Registration Number: NCT00373451

Locations: 🇩🇪
Medizinische Klinik, Klinikum rechts der Isar, Muenchen, Germany
🇩🇪
Herz-Zentrum Bad Krozingen, Bad Krozingen, Germany
🇩🇪
Herz- und Gefaessklinik, Kardiologie, Bad Neustadt, Germany

and more 6 locations

Palifermin DDI (Drug Drug Interaction)

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Palifermin
Drug: Heparin

First Posted Date: 2006-08-08

Last Posted Date: 2014-11-06

Lead Sponsor: Swedish Orphan Biovitrum

Target Recruit Count: 45

Registration Number: NCT00361348

Study Comparing Desirudin With Heparin to Prevent Vein Clots After Heart and Lung Surgery

Phase 2

Completed

Conditions: Deep Venous Thrombosis

Interventions: Drug: Desirudin (Iprivask™)
Drug: Heparin

First Posted Date: 2006-05-24

Last Posted Date: 2019-03-05

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 120

Registration Number: NCT00329433

Locations: 🇺🇸
Barnes-Jewish Hospital, Saint Louis, Missouri, United States

Study of Otamixaban Versus Unfractionated Heparin (UFH) and Eptifibatide in Non-ST Elevation Acute Coronary Syndrome

Phase 2

Completed

Conditions: Coronary Disease

Interventions: Drug: Otamixaban (XRP0673)
Drug: unfractionated heparin
Drug: eptifibatide

First Posted Date: 2006-04-24

Last Posted Date: 2014-12-03

Lead Sponsor: Sanofi

Target Recruit Count: 3241

Registration Number: NCT00317395

Locations: 🇹🇷
Sanofi-Aventis Administrative Office, Istanbul, Turkey

Efficacy and Safety of Low-molecular Weight Heparin for Thromboprophylaxis in Acutely Ill Medical Patients

Phase 3

Completed

Conditions: Embolism

Interventions: Drug: Certoparin
Drug: Heparin

First Posted Date: 2006-04-06

Last Posted Date: 2017-02-24

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 342

Registration Number: NCT00311753

Locations: 🇨🇭
Novartis Pharmaceuticals, Basel, Switzerland

Innohep® in Elderly Patients With Impaired Renal Function Treated for Acute Deep Vein Thrombosis

Phase 4

Completed

Conditions: Deep Vein Thrombosis

Interventions: Drug: innohep®
Drug: Heparin

First Posted Date: 2006-01-16

Last Posted Date: 2019-03-15

Lead Sponsor: LEO Pharma

Target Recruit Count: 541

Registration Number: NCT00277394

Locations: 🇫🇷
Hôpital de la Cavale Blanche, Brest, France
🇧🇬
Bulgaria - managed by CRO, Sofia, Bulgaria
🇨🇿
Czech Republic - managed by CRO, Praha, Czechia

and more 6 locations